What is TCBPY stock price today?

TCBPY (TC Biopharm (Holdings) Plc) stock is trading at $0.05 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is TCBPY stock going up or down today?

TCBPY stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy TCBPY stock now?

The decision to buy TCBPY depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is TCBPY a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for TCBPY based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is TCBPY stock overvalued or undervalued?

Use our DCF valuation calculator to determine if TCBPY is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is TCBPY's P/E ratio?

P/E ratio data for TCBPY will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is TCBPY's market cap?

Visit our dashboard for TCBPY's current market capitalization and other key metrics.

What is TCBPY's price to book ratio?

TCBPY trades at a price-to-book (P/B) ratio of 0.11, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does TCBPY pay dividends?

TCBPY does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is TCBPY's dividend yield?

TCBPY does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is TCBPY stock a good long-term investment?

TCBPY's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is TCBPY's revenue growth rate?

Revenue growth data for TCBPY is available on our dashboard with detailed financial statement analysis.

Profitability metrics for TCBPY are available on our dashboard with complete income statement analysis.

What are the risks of investing in TCBPY?

Key risks for TCBPY include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does TCBPY compare to its competitors?

Compare TCBPY to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize TCBPY's performance and positioning.

What is TCBPY's stock price target for 2026?

Our AI model provides price targets for TCBPY based on fundamental analysis: Bull case $0.07 (+30%), Base case $0.06 (+15%), Bear case $0.05 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about TCBPY?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for TCBPY. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is TCBPY's next earnings report?

TCBPY reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

TCBPY - TC Biopharm (Holdings) Plc

NYSE * Healthcare * Biotechnology

$0.05

+$0.00 (+0.00%)

About TC Biopharm (Holdings) Plc

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TCBPY Key Statistics

Market Cap

$0.00M

P/B Ratio

0.11

Employees

How TCBPY Compares to Peers

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

N/A

of 5

Size Rank

N/A

of 5

Company	Market Cap	P/E	Growth	Margin	Compare
TCBPY(This stock)	$0.00	N/A	0%	0.0%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

TC Biopharm (Holdings) Plc Company Information

Headquarters: Maxim 1, Motherwell, United Kingdom, ML1 4WR, undefined
Website: tcbiopharm.com
Sector: Healthcare
Industry: Biotechnology

Data Updated: April 17, 2026 at 4:54 AM EDT

Ready to invest in TCBPY?

Commission-free trading available. Affiliate links.

Upcoming Events for TCBPY

Dashboard

Enter a ticker to analyze